Document Detail


Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new.
MedLine Citation:
PMID:  23298840     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CLINICAL VIGNETTE: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?
Authors:
L Darryl Quarles
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2013-01-09
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  123     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-04-19     Completed Date:  2013-05-13     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  542-3     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / mortality,  physiopathology,  prevention & control*
Fibroblast Growth Factors / physiology
Humans
Hypertrophy, Left Ventricular / etiology,  physiopathology
Male
Middle Aged
Renal Insufficiency, Chronic / complications*,  drug therapy*
Renin-Angiotensin System / drug effects,  physiology
Translational Medical Research
Grant Support
ID/Acronym/Agency:
AR045955/AR/NIAMS NIH HHS; DK083303/DK/NIDDK NIH HHS; DK095812/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/fibroblast growth factor 23; 62031-54-3/Fibroblast Growth Factors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multiple functions of a glioblastoma fusion oncogene.
Next Document:  The implementation of liquid chromatography tandem mass spectrometry for the official control of lip...